Coronavirus Update: Will Dexamethasone Breakthrough Make Remdesivir Irrelevant?
Plus AZ's Vaccine May Only Protect For One Year
Executive Summary
The RECOVERY trial has produced clear results for the cheap steroid treatment dexamethasone. What does it mean for Gilead's antiviral remdesivir?
You may also be interested in...
Sanofi Pairs Up With Non-Profit Protas In Quest To Cut Clinical Trial Costs
The French major has committed up to £5m for non-profit Protas, which aims to facilitate large clinical studies at a fraction of the usual price and form more pharmaceutical collaborations down the line.
Flutter Over Biocon’s Repurposed Psoriasis Drug For COVID-19 In India
Biocon’s itolizumab gets clearance in India for restricted emergency use in COVID-19 patients, amid some concerns around small study numbers. But company says data are compelling and cites compassionate use substantiation, while partner Equillium expects to pursue a global study under US IND.
‘Agile’ Approach Aims To Accelerate Ridgeback’s COVID-19 Timeline
The Bayesian adaptive trial design is looking to slash development times, starting with a Phase II trial of Ridgeback’s drug, a potential challenger to Gilead’s remdesivir.